Zur Hauptnavigation wechseln
Zur Suche wechseln
Zum Hauptinhalt wechseln
Technische Universität München Home
Hilfe und FAQ
Link wird in einem neuen Tab geöffnet
English
Deutsch
Inhalt suchen unter Technische Universität München
Home
Personen
Einrichtungen
Projekte
Publikationen
Ausstattungen/Einrichtungen
Auszeichnungen
Aktivitäten
Presseberichte
Immunonkologie - ein Überblick
Sebastian Kobold
,
Angela Krackhardt
, Hans Schlösser
, Dominik Wolf
Klinik und Poliklinik für Innere Medizin III, Hämatologie und Onkologie
Ludwig-Maximilians-Universität München (LMU)
Publikation
:
Beitrag in Fachzeitschrift
›
Artikel
›
Begutachtung
7
Zitate (Scopus)
Übersicht
Fingerprint
Fingerprint
Untersuchen Sie die Forschungsthemen von „Immunonkologie - ein Überblick“. Zusammen bilden sie einen einzigartigen Fingerprint.
sortieren
Gewicht:
Alphabetisch
Keyphrases
T Cells
100%
Immuno-oncology
100%
Successful Implementation
50%
Cell Therapy
50%
Standard of Care
50%
Cancer Patients
50%
Cancer Types
50%
Programmed Death-ligand 1 (PD-L1)
50%
Response Rate
50%
Immune System
50%
Bispecific Antibody
50%
T Cell Activation
50%
Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4)
50%
Clinical Development
50%
B-cell Lymphoma
50%
Immunotherapeutic Approaches
50%
Overall Survival
50%
Melanoma Cells
50%
Metastatic Melanoma
50%
CD19 chimeric Antigen Receptor T Cells
50%
CD19
50%
Tumor Control
50%
Non-small Cell Lung Cancer (NSCLC)
50%
Lymphatics
50%
Tumor Disease
50%
B-cell Leukemia
50%
Malignant B Cells
50%
Inhibitory Antibody
50%
Blinatumomab
50%
Treatment Modalities
50%
Genetically Engineered
50%
Clinical Tumor
50%
Medicine and Dentistry
Neoplasm
100%
Malignant Neoplasm
100%
T Cell
100%
Immunoglobulin
100%
Oncology
100%
Immunotherapy
100%
Acute Lymphocytic Leukemia
100%
Receptor
50%
Lymph Duct
50%
Cancer Types
50%
Chimeric Antigen Receptor
50%
T Cell Activation
50%
Bispecific Antibody
50%
B-Cell Lymphoma
50%
CTLA-4
50%
Overall Survival
50%
Non Small Cell Lung Cancer
50%
Programmed Death-Ligand 1
50%
B Cell Leukemia
50%
Immune System
50%
Metastatic Melanoma
50%
Blinatumomab
50%
CD3 Antigen
50%
Diseases
50%
Treatment Modality
50%
Side Effect
50%
Immunology and Microbiology
B Cell
100%
Intravenous Immunoglobulin
100%
CD19
100%
Immunotherapy
100%
T Cell
100%
Programmed Death-Ligand 1
50%
T Cell Activation
50%
Lung
50%
Overall Survival
50%
Chimeric Antigen Receptor
50%
Bispecific Antibody
50%
CTLA-4
50%
CD3 Antigen
50%
Immune System
50%
Blinatumomab
50%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Immunoglobulin
100%
Neoplasm
66%
Immunotherapy
66%
Blinatumomab
33%
Overall Survival
33%
Receptor
33%
Chimeric Antigen Receptor
33%
Non Small Cell Lung Cancer
33%
Bispecific Antibody
33%
Metastatic Melanoma
33%
B Cell Leukemia
33%
B Cell Lymphoma
33%
CD3 Antigen
33%
Cytotoxic T Lymphocyte Antigen 4
33%
Diseases
33%
Side Effect
33%